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Abstract: Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the 
skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis 
population. Treatment of this group is challenging due to the long-term side effects, toxicities and 
inconvenience of conventional treatments such as phototherapy, methotrexate and cyclosporine. 
However, recent advances in our understanding of the pathogenesis of psoriasis have led to the 
popular use of biologics, which offer a safer, more convenient and effective targeted therapy. 
Adalimumab was originally approved for treating rheumatoid arthritis. Currently, adalimumab 
is also approved for treatment of adult patients with moderate to severe chronic plaque psoriasis 
who are candidates for systemic therapy or phototherapy or when other systemic therapies are 
medically less appropriate. Since the onset of the use of biologics, there have been concerns 
over safety and efficacy when used as long-term therapy. This paper reviews all publications, 
posters and abstracts reporting original data on the efficacy and/or safety of adalimumab in 
patients treated for chronic plaque psoriasis for more than 1 year.
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Introduction
Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the 
skin and joints with an estimated world-wide prevalence of 3%. Accurate diagnosis 
is important due to recent evidence that psoriasis may be associated with other 
co-morbidities such as metabolic disorders, obesity and may be an independent risk 
factor for cardiovascular disease.1 The most common form of psoriasis is plaque 
psoriasis, which constitutes around 80% to 90% of psoriasis patients. Other less 
common forms include inverse, erythrodermic, pustular, and guttate psoriasis.2
Psoriatic arthritis (PsA) is an inflammatory arthritis characterized by pain, swelling 
and stiffness of the joints that affects between 6% to 42% of patients with psoriasis. 
Joint symptoms often precede skin manifestations of the disease by an average of 
10 years.3
Patients with moderate to severe psoriasis constitute about 30% of the psoriasis 
population. These patients are determined by a score greater than 10 on several indices 
including: total body surface area (TbSA 1%–100%), psoriasis area and severity index 
(PASI 0–72), and dermatology quality of life index (DQLI 1–30). This subset of patients 
presents a challenge due to the long-term side effects, toxicities and inconvenience of con-
ventional treatments such as phototherapy, methotrexate and cyclosporine. However, recent 
advances in our understanding of the pathogenesis of psoriasis have led to the popular use 
of biologics, which offer a safer, more convenient and effective targeted therapy.4Clinical, Cosmetic and Investigational Dermatology 2010:3 50
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Recently, several studies suggest that patients with severe 
psoriasis may have an increased risk for cardiovascular dis-
ease, depressive illness, lymphoma (Hodgkin’s lymphoma 
and cutaneous T-cell lymphoma), and a decreased life 
expectancy.5–10
We systematically reviewed all published articles, posters, 
and abstracts reporting original data concerning the efficacy 
and/or safety of adalimumab in chronic plaque psoriasis for 
more than 1 year. Relevant articles were identified by search-
ing Medline from its inception until December, 2009 for com-
binations of the search terms “psoriasis” and “adalimumab”. 
Animal studies were excluded. No persons other than the 
authors of this manuscript were involved in the design, analy-
sis, and interpretation of data, in the writing of the report, and 
in the decision to submit the article for publication.
Pathogenesis of psoriasis
The pathogenesis of psoriasis is currently viewed as a disorder 
of TH1 cell-mediated immunity. Tumor necrosis factor α 
(TNF-α), which is a natural occurring cytokine, is elevated 
in the plaques as well and in the synovial joints and serum in 
psoriasis patients. TNF-α appears to be responsible for the 
keratinocyte hyperproliferation, endothelial cell regulation, 
and recruitment and activation of memory T cells that perpetu-
ate the inflammatory response in psoriasis.7 TNF-α, produced 
by activated T-cells, promotes the inflammatory response 
by activating nuclear factor κB, leading to the induction of 
interleukin (IL1)/6/8 and to the up-regulation of adhesion mol-
ecules on endothelial cells. These interleukins are responsible 
for the up-regulation of adhesion molecules on endothelial 
cells.4 IL-23 has also been found in increased levels and 
stimulates the survival and proliferation of TH17 cells. More 
research is needed to access the role in the TH17 pathway 
in the pathogenesis of psoriasis, as it may play a key role in 
effective treatment options.8
Anti-TNF agents
Anti-TNF-α agents block the inflammatory effects of TNF-α 
and include adalimumab, infliximab, and etanercept. Block-
ing TNF-α may also inhibit the Th17 pathway. These TNF 
agents have become popular treatment options for a variety 
of inflammatory disorders including psoriasis and PsA.4
Pharmacology and recommended 
dosing of adalimumab
Adalimumab is the first fully humanized recombinant mono-
clonal antibody that is indistinguishable in structure and 
function from naturally occurring IgG1. Adalimumab binds 
to both soluble and cell-bound TNF-α and prevents TNF-α 
interaction with the p55 and p75 cell surface TNF receptors. 
Adalimumab lyses surface TNF expressing cells in vitro 
in the presence of complement and also induces apoptosis 
in cells expressing surface TNF-α, thereby neutralizing 
its effects and improving joint and skin manifestations.12 
In addition, adalimumab modulates biological responses 
that are induced or regulated by TNF, including changes in 
the levels of adhesion molecules responsible for leukocyte 
migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 
of 1–2 × 10−10 M).12
According to the therapeutic window concept,9 the steady-
state range of serum or tissue drug concentrations should be 
adequate for neutralization of surplus TNF, but not so high 
as to threaten safety because of neutralization of homeostatic 
concentrations of TNF required for host defense, or so low 
as to impair efficacy from suboptimal neutralization of 
TNF. Recommended dosing for the treatment of psoriasis is 
80 mg given subcutaneously at week one, 40 mg given sub-
cutaneously at week 2, followed by regular dosing of 40 mg 
subcutaneously administered every 2 weeks thereafter.10 
Adalimumab given 40 mg subcutaneously every other week 
produces steady-state serum trough concentrations of 4 to 
8 µg/mL, which are 3 to 7 times greater than the clinically 
effective serum concentrations (0.8–1.4 µg/mL).11 The sys-
temic clearance of adalimumab is approximately 12 mL/h. 
Once therapy is initiated, the drug reaches its peak around 
5.5 days and has a half-life of approximately 14 days ranging 
from 10 to 20 days across studies. Mean serum adalimumab 
trough levels at steady state increases proportionally with 
dose following 20, 40, and 80 mg every other week and 
every week subcutaneous dosing.10 In long-term studies with 
dosing more than 2 years, no evidence exists of changes in 
clearance over time.
Current approval
Adalimumab is currently Food and Drug Administration 
(FDA) and European Medicines Agency (EMEA) approved 
for the treatment of PsA, rheumatoid arthritis (RA), Crohn’s 
disease (CD), juvenile idiopathic arthritis (JIA), ankylosing 
spondylitis (AS), and, more recently, moderate to severe 
plaque psoriasis.10 Specifically, in the US, adalimumab 
is approved for treatment of adult patients with moderate 
to severe chronic plaque psoriasis who are candidates for 
systemic therapy or phototherapy or when other systemic 
therapies are medically less appropriate. Before starting treat-
ment with adalimumab, a complete history and physical exam 
should be performed. Recommended labs include a complete Clinical, Cosmetic and Investigational Dermatology 2010:3 51
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blood cell count, chemistry panel with liver function tests, 
hepatitis panel, and tuberculosis (Tb) testing at baseline and 
at variable frequencies thereafter.14
Limited safety experience exists on surgical procedures 
in patients treated with adalimumab. The long half-life of 
the drug should be taken into consideration, and a patient 
requiring surgery should be closely monitored for infections. 
Patients on adalimumab may receive concurrent vaccinations, 
except for live vaccines. No data currently exist on secondary 
transmission of infection by live vaccines in patients receiv-
ing adalimumab therapy.16 Adalimumab did not diminish 
response to pneumococcal and influenza virus vaccines in 
RA patients.17
Adalimumab is a pregnancy category B drug.18 Because 
of the possible impact on newborn’s immune responses, 
adalimumab treatment in women of reproductive age requires 
contraception during treatment and at least 5 months after the 
last administered dose. Women should not breast feed for at 
least 5 months after the last adalimumab treatment.14
Patients with RA treated with adalimumab during the first 
trimester of pregnancy were followed by the Organization 
of Teratology Information Specialists (OTIS) throughout 
pregnancy and for 1 year post partum and compared with 
those from a disease-matched group of pregnant women with 
RA without adalimumab treatment during pregnancy, and a 
healthy (ie, non-diseased) group of women who neither had 
RA nor had been treated with adalimumab.18 In addition, 
OTIS investigators collected information on patients with 
psoriasis or other diseases treated with adalimumab. Based 
on these preliminary data, no increases in major structural 
defects or major malformations were seen in women with 
adalimumab exposure. The following perinatal complications 
were observed: Prematurity, neonatal jaundice, neonatal 
urinary Escherichia coli infection, and adrenal congenital 
hyperplasia of probable hereditary origin. However, more 
recently, data that had been reported to the FDA on children of 
pregnant mothers taking a TNF-α antagonist have uncovered 
a more significant increase in congenital anomalies consistent 
with those seen in VACTERL association.19 Based on these 
data, we agree with the suggestion that clinicians should 
probably not prescribe TNF antagonists to women during 
pregnancy since human experience is still extremely limited, 
particularly in patients with psoriasis.
Efficacy and safety concerns based 
on previous RA studies
To date, most large-scale safety assessments of adalimumab 
are based on trials of patients with RA. Patients with RA are 
often treated with the combination of TNF inhibitors and an 
immunosuppressive agent such as methotrexate, while patients 
with psoriasis are often treated with the TNF inhibitors as 
monotherapy. The extrapolations on the safety of TNF inhibi-
tors derived from this combination therapy data may actually 
overestimate the potential risk of these agents when used as 
monotherapy in psoriasis.14 It is important to be aware of 
potential adverse events that have been reported with the use of 
adalimumab in RA studies. Serious adverse events of concern 
are discussed below. However, the safety data based on RA 
studies should only be cautiously compared between other 
indications such as moderate to severe plaque psoriasis, due 
to differences in co-morbidities and patient populations.
Studies of RA patients have shown that the most com-
mon adverse events associated with adalimumab therapy are 
injection-site reactions. They are usually mild and include 
local erythema and pruritus. In clinical studies, 53% of 
adalimumab patients with RA developed infections compared 
with 47% of placebo-treated patients. Other common adverse 
events include upper respiratory tract infections, rhinitis, 
bronchitis and urinary tract infections.16
The incidence of serious infections in studies of RA 
patients was under 2%. However, patients with underlying 
predisposing medical conditions are at a higher risk. Rare 
opportunistic infections, including histoplasmosis, cryptococ-
cosis, aspergillosis, coccidioidomycosis, candidiasis, listeriosis 
and pneumocystis, have been reported. Most of these patients 
were also treated with other immunosuppressive agents, such 
as methotrexate, systemic corticosteroids, or both.16
In the event of an infection requiring antibiotic therapy, 
adalimumab should be withheld and appropriate treatment 
should be initiated. However, in the event of more serious 
infections or opportunistic infections, adalimumab should be 
discontinued and the patient should be treated appropriately.20 
Treatment with TNF inhibitors should be avoided if possible 
in patients with chronic, serious, or recurring infections.14
Registry data from patients with RA and post market-
ing reports to the FDA have identified numerous cases 
of Tb reactivation associated with all TNF inhibitors.14 
Extrapulmonary or disseminated cases of Tb occurred in 
7 patients on anti-TNF therapy during the first 534 patient-
years of adalimumab exposure in clinical trials; the rate of Tb 
decreased by 75% in European trials after the introduction 
of routine Tb screening. The FDA currently recommends Tb 
screening with a purified protein derivation before beginning 
anti-TNF therapy.16 A tuberculin skin test (PPD) or quantif-
eron Gold serum assay can be used to screen for Tb.14 For 
patients about to initiate anti-TNF therapy, a positive test Clinical, Cosmetic and Investigational Dermatology 2010:3 52
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is read if greater than 5 mm induration is observed at 48 to 
72 hours. For a positive PPD reading, a follow-up chest X-
ray is indicated to rule out an active infection. If a patient is 
diagnosed with a latent infection, prophylaxis with 9 months 
of isoniazid is warranted. Anti-TNF therapy may be initi-
ated after 1 to 2 months only if the patient is adhering to 
and tolerating the isoniazid therapy. Patients with active Tb 
should be appropriately referred to a specialist to begin the 
standard 4-drug treatment. Concurrent anti-TNF therapy is 
contraindicated in active Tb.20
In trials of patients with RA treated with adalimumab, 
the incidence rate of lymphomas was 3.1. Risk of lymphoma 
is substantially increased in a subset of patients with very 
severe RA, regardless of previous treatment types. High 
inflammatory activity, rather than its treatment, is a major 
risk determinant.21 Further investigation is warranted to 
evaluate if TNF inhibitors are associated with increased 
lymphoma rates.
Patients treated with adalimumab tend to have a higher 
incidence of demyelinating conditions, especially multiple 
sclerosis (MS). MS has been reported to develop in and also 
worsen in patients taking TNF inhibitors. However it has 
been suggested that psoriasis and RA patients have a higher 
incidence of MS compared to the general population.16 TNF 
inhibitors should be avoided in the setting of a personal his-
tory of demyelinating conditions or patients with first-degree 
relatives with MS.14
To determine the hazard risk of developing or worsening 
heart failure, RA patients treated with infliximab, etanercept, 
or adalimumab (n = 2757) or conventional disease-modifying 
anti-rheumatic drugs (controls; n = 1491) in a German 
biologics register were studied.22 No evidence was found 
of an increased risk of heart failure with TNF-α inhibitors, 
especially if no concomitant treatment with glucocorticoids 
or cyclooxygenase 2 inhibitors is given. Since exacerbation 
of chronic heart failure (CHF) has been reported with TNF 
inhibitors, however, it has been recommended that adali-
mumab be avoided in patients with severe CHF (class III 
or IV) and discontinued in those with mild disease during a 
CHF exacerbation.23
Data suggest there may be a risk of hepatotoxicity and 
hepatitis B reactivation in adalimumab patients. Whereas 
TNF-α may promote viral clearance in hepatitis B, it is 
thought to promote chronic liver injury in hepatitis C, with 
elevated levels of TNF-α in patients with hepatitis C com-
pared to the general population. A few reports have stated 
that anti-TNF treatment in hepatitis C is safe and well toler-
ated by patients and may even be beneficial.24 Consultation 
with liver specialists as indicated may be appropriate when 
considering the use of anti-TNF therapy in this setting. 
There is an FDA warning suggesting that patients who have 
concurrent hepatitis B infection should not be treated with 
any of the TNF inhibitors.14
The safety and efficacy of adalimumab in immunosup-
pressed patients have not been evaluated. HIV is listed among 
the relative contraindications for anti-TNF therapy. Because 
clinical trials have excluded patients with HIV/AIDS, limited 
data are available. However, in a study of 64 RA patients 
there was no evidence of depression of delayed-type hyper-
sensitivity, depression of immunoglobulin levels or change 
the number of effector T and B cells, natural killer cells, 
monocytes, macrophages or neutrophils. There have been 
several case reports of HIV patients treated with etanercept 
and infliximab in which there did not appear to be an increase 
in morbidity or mortality.16 In some patients, some symptoms 
of HIV/AIDS such as aphthous ulcers, cachexia, dementia, 
and fatigue actually improved with TNF blockade. HIV/
AIDS patients who are well controlled on antiviral therapy 
and have failed all other treatment options may be carefully 
selected for anti-TNF therapy under careful surveillance of 
their physician.24 However, there are no conclusive data and 
no specific recommendations in the current guidelines.
In a prospective cohort study, in which 289 RA patients 
on anti-TNF therapy were followed through the course of 
several years, 128 dermatological events were recorded in 
72 patients.12 In placebo-controlled randomized clinical trials 
on adalimumab in RA patients, conversion rates of patients 
with negative ANA at baseline to positive ANA occurred in 
11% to 26% of RA patients treated with adalimumab, and 
5.5% to 15.2% of RA patients who received placebo.26,27 
Interestingly, 5% to 44% of RA patients converted from 
ANA(+) to ANA(–). Presenting manifestations were mostly 
cutaneous lesions, photosensitivity and serositis.27 No evi-
dence exists that developing ANA, anti-DNA antibodies or 
anticardiolipin antibodies while on TNF antagonist therapy 
increases the risk of developing clinical systemic lupus ery-
thematous (SLE)-type syndromes.28
However, one case of clinical SLE and 2 cases of cuta-
neous lupus have been identified in patients shortly after 
initiating adalimumab in RA patients in clinical practice. 
VanRijthoven et al described clinical symptoms of SLE 
in a 56-year-old female with RA who was loss response 
to infliximab so then switched to adalimumab.29 ANA and 
anti-dsDNA were positive at the initiation of adalimumab 
therapy and clinical symptoms of lupus (no organ involve-
ment) ensued after 4 injections of adalimumab. Resolution of Clinical, Cosmetic and Investigational Dermatology 2010:3 53
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symptoms occurred after treatment with IV dexamethasone 
and adalimumab was discontinued. Spillane et al described 
a 40-year-old female with RA who developed biopsy-proven 
discoid lupus after her second to fourth doses of adalim-
umab.30 The patient had previously completed an 8-month 
course of etanercept but had switched to adalimumab. ANA 
and extranuclear antibodies panels were negative. Adali-
mumab was discontinued and the patient was restarted on 
etanercept 1 month later. No new lesions developed, and 
the existing lesions resolved with topical steroids. Sheth 
et al reported a 51-year-old female who developed a rash 
10 days after starting adalimumab (40 mg every other 
week) for seropositive RA.31 She developed biopsy-proven 
subacute cutaneous lupus erythematosus on her arms and 
chest but no systemic symptoms, neurological symptoms, 
nor serositis. Symptoms resolved without treatment 2 weeks 
after discontinuing adalimumab. Family history was positive 
for SLE with renal and cutaneous involvement.
Efficacy of adalimumab in the  
long-term treatment of moderate 
to severe plaque psoriasis and 
psoriatic arthritis
Even though adalimumab has only been evaluated for up to 
100 weeks for chronic plaque psoriasis, the efficacy and safety 
of adalimumab therapy has been evaluated up to 120 weeks 
for PsA.32 The ADEPT trial evaluated the long-term efficacy 
and safety in PsA over a 2-year period. Of particular interest 
is the efficacy of adalimumab in the clearance of skin lesions 
as well as the long-term safety profile. It is important to note 
that patients who were on non-steroidal anti-inflammatory 
agents, disease-modifying anti-rheumatic drugs or prednisone 
before the trial could continue these medications throughout 
the study. In this placebo-controlled trial, 298 patients com-
pleted a 24-week double-blind period; 285 patients were then 
enrolled in an open-label extension study and received 40 mg 
adalimumab subcutaneous every other week for up to an addi-
tional 120 weeks. Skin assessments were restricted to patients 
with at least 3% body surface area involvement at enroll-
ment. Notably, greater than 20% achieved and maintained 
a PASI 100 at 48 weeks and 56.6% had a physicians global 
assessment (PGA) of clear or almost clear at 104 weeks. The 
percentage of patients achieving PASI 50, PASI 75, PASI 90, 
or PASI 100 changed by 10% or less from week 48 through 
2 years of adalimumab treatment. Skin-related improvements 
that were present after 48 weeks of adalimumab therapy were 
maintained through 2 years of therapy for most patients.32
To compare treatment effectiveness as well as patient 
satisfaction and tolerability of the TNF-α antagonists, 
Heiberg et al compared the discontinuation rates of 
adalimumab, infliximab, and etanercept in patients with 
PsA, RA, and AS.33 150 patients were treated with 172 anti-
TNF-α treatment courses in patients with PsA (adalimumab 
n = 28; infliximab n = 48; etanercept n = 96). Concomitant 
methotrexate therapy (68%) was associated with lower with-
drawal rates of all three anti-TNFα agents. Discontinuation 
rates were lower for adalimumab (14.3%) than for infliximab 
(25.0%) or etanercept (24.0%). These data suggest that 86% 
of patients treated with adalimumab maintained acceptable 
efficacy, patient satisfaction, and tolerability to maintain 
compliance.
In phase II double-blind, randomized controlled clinical 
trials of adalimumab in chronic plaque psoriasis, in the open-
label extension arm, patients who received adalimumab for 
60 weeks for plaque psoriasis achieved PASI 75 in 56% of 
the every other week, 64% of the every week, and 45% of 
the placebo/eow groups. Total clearance (PASI 100) at week 
60 was observed in 16% of the every other week group, 26% 
of the every week group and 19% in the placebo/every other 
week group.34
In a phase III double-blind, randomized-controlled clinical 
trials of adalimumab 40 mg every other week in 1212 patients 
with moderate-to-severe plaque-type psoriasis, Menter et al 
reported initial PASI-75 response rates of 71% after 16 weeks 
and 70% after 24 weeks of treatment.35 Patients who had met 
the PASI-75 response criterion were re-randomized at week 
33 to continue treatment with adalimumab or switched to 
placebo until week 52. Loss of response over the 19 weeks, 
defined as PASI 50 and 6 point increase in PASI, was 
observed in 5% of patients continuing adalimumab therapy 
and 28% of patients switched to placebo. Based on these 
findings, loss of response after continuous treatment with 
adalimumab over 1 year was 5% while sustained efficacy was 
seen in 72% of patients for 19 weeks after discontinuation 
of adalimumab treatment.
A small retrospective study by Van et al evaluated 49 
patients with moderate-to-severe plaque psoriasis who 
has lack of or loss of efficacy with prior biologic therapy 
including infliximab and/or etanercept. After 12 months 
of adalimumab therapy, 78% of patients were considered 
as “clear” or “almost clear” according to PGA of disease 
severity. Five patients (10%) stopped adalimumab due to 
lack of effectiveness.36 Thus, it appears that prior treatment 
with another TNF-α antagonist does not significantly appear 
to diminish response to adalimumab.Clinical, Cosmetic and Investigational Dermatology 2010:3 54
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Although loss of efficacy over time has been observed in 
patients receiving infliximab, this does not appear to be an 
issue for adalimumab based on published data.37 In contrast, 
efficacy in patients with psoriasis treated continuously with 
adalimumab for 100 weeks sustained PASI 75 responses in 
83% and PASI 100 responses in 32%, with a PGA score of 
“clear” or “minimal” in 70%.38 Similar efficacy was seen in 
patients with moderate to severe plaque psoriasis and PsA 
treated with adalimumab for 2 years.39
Mentor et al also assessed for the presence of anti-
adalimumab antibodies (AAAs).35 8.8% had detectable 
AAAs during the 52-week treatment period. Three of 
7 AAA-positive patients, compared with 65 of 233 AAA-
negative patients, lost an adequate response. The presence of 
AAAs was not correlated with any treatment-related adverse 
events, including serious adverse events and injection-site 
reactions. Some patients who developed AAAs demonstrated 
reduced efficacy. However, because the percentage of patients 
who developed antibodies to adalimumab was small, the 
overall involvement of AAAs in reduction of efficacy was 
minimal.35
Safety and tolerability  
of adalimumab in the long-term 
treatment of plaque psoriasis 
and psoriatic arthritis
The safety profile of adalimumab in phase II clinical trials 
during long-term treatment of PsA and psoriasis was consis-
tent with the safety profile of previous adalimumab studies.32 
No clinically meaningful changes in the type and frequency 
of adverse events were observed with 24 versus 48 weeks of 
adalimumab treatment. No significant changes in laboratory 
values were seen, besides the desired effect of a decrease in 
C-reactive protein. No new safety signals were seen compared 
to rheumatoid arthritis. Specifically, no indication of an increase 
in such TNF-associated adverse events such as Tb, malignan-
cies, demyelinating disease, CHF, or SLE were observed. 
Through 2 years of adalimumab exposure, only 1 report of 
peritoneal Tb, 4 of oral candidiasis, 1 of non-Hodgkin’s lym-
phoma, 2 of basal cell carcinoma, and 1 with a neuroendocrine 
carcinoma of the skin occurred. Three deaths occurred among 
the 298 patients. Two patients experienced cardiopulmonary 
arrest from a myocardial infarction, which was probably not 
related to adalimumab. The third patient experienced sudden 
death that was attributed to acute pulmonary edema and was 
considered to be possibly related to adalimumab.32
In phase-II clinical trials on patients receiving adalimumab 
for 60 weeks, adalimumab was generally well tolerated, with 
9% of patients discontinuing therapy due to an adverse event. 
No significant laboratory abnormalities were observed. The 
most frequently reported side effects included nasopharyngitis 
and upper respiratory infection as well as pain at the injection 
site. Fourteen patients experienced a serious adverse event 
during the 60-week period, being more common in the patients 
receiving adalimumab weekly (11 patients). Serious adverse 
events included 2 cases of malignant melanoma, 1 case of 
squamous cell carcinoma, 2 cases of cerebrovascular events, 
1 case of breast carcinoma, 1 case of gastric adenocarcinoma, 
1 case of coccidiomycosis and 2 cases of Tb.34
Burmester et al performed a safety analysis in 19, 041 
patients exposed to adalimumab using data from 36 global 
clinical trials though April 15, 2007, and concluded that the 
overall malignancy rates and the all-cause mortality rates for 
adalimumab treated patients were as expected for the general 
population.40 Safety data were included from adalimumab stud-
Table 1 Compiled safety data (rates per 100 patient-years) for serious adverse events for adalimumab in different FDA-approved 
indications
Established safety profile for adalimumab
Indication Ps PsA RA AS JIA CD
exposure (PY) 135 484 12,506 423 99 1,506
Patients (N) 142 395 10,050 393 171 1,459
Serious infections 0.74 2.07 5.05 1.18 4.04 5.98
Tuberculosis 0.00 0.00 0.27 0.00 0.00 0.20
Lymphoma 0.00 0.41 0.12 0.24 0.00 0.07
Demyelinating disease 0.00 0.00 0.08 0.00 0.00 0.13
SLe/lupus-like 0.00 0.00 0.10 0.00 0.00 0.07
CHF 0.00 0.00 0.28 0.00 0.00 0.00
Abbreviations: CHF, congestive heart failure; SLe, systemic lupus erythematous; PY, patient-years; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; AS, ankylosing 
spondylitis; JIA, juvenile idiopathic arthritis; CD, Crohn’s disease.Clinical, Cosmetic and Investigational Dermatology 2010:3 55
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ies in PsA, RA, AS, CD, and JIA. Data revealed that the average 
psoriasis patient treated with adalimumab was 44 years of age, 
which is 10 years younger than the average RA patient. Also, 
61.8% of RA patients were on concomitant immunosuppres-
sive therapy and 58.6% were on concomitant systemic steroid 
therapy compared to only 0.3% and 1.2% of psoriasis patients, 
respectively. Cumulative rates of adverse events in RA patients 
treated with adalimumab have remained stable over 10 years. 
Rates of adverse events for psoriasis patients in adalimumab 
trials were lower compared to those with RA in adalimumab 
trials, while rates of adverse events for PsA, AS, CD, and JIA 
were similar to or lower than rates for RA (Table 1). Overall 
malignancy and mortality rates for adalimumab-treated psoria-
sis patients were comparable to the general population.40
The monthly incidence rate of injection-site reactions 
in published clinical trials ranged from 1.2%41 to 3.4%34 
(Table 3). Within 2 years of exposure to adalimumab, 20/298 
patients with PsA discontinued treatment due to adverse 
events.32 Of 3 patients (1.0%) who died within the observa-
tion period, 2 had myocardial infarction, which was classified 
as probably not related to adalimumab, and 1 experienced 
sudden death after acute pulmonary edema, which was 
classified as possibly related to adalimumab.32 No deaths 
were observed in the other clinical trials included in this 
systematic review.34,35,43,44 Possibly from the associations of 
co-morbidities with psoriasis and PsA, the randomized clini-
cal trial by Genovese et al to assess the efficacy and safety of 
adalimumab for PsA found significantly more adverse events 
in patients receiving placebo compared to those receiving 
adalimumab (P  0.01).44
Despite the fact that patients were screened for latent Tb 
prior to inclusion and not eligible if Tb was suspected unless 
Tb treatment had been initiated already in clinical trials, 
3 cases of Tb were observed in the randomized, placebo-
controlled clinical trials (Table 2).34,35 Other severe infections 
observed in clinical trials assessing adalimumab for psoriasis 
included coccidioidomycosis (n = 1)34 and viral meningitis 
(n = 1)32,40,41 No cases were reported of opportunistic infec-
tions in psoriasis patients treated with adalimumab, although 
a series of cases with Legionella pneumophila pneumonia has 
been reported in RA patients treated with adalimumab.45
Cases of demyelination, optic neuritis, and MS have not 
been observed in clinical trials of adalimumab for patients 
with plaque psoriasis or PsA (Table 2). Chung et al report 
a case of optic neuritis in a psoriasis patient who had been 
treated for a year with adalimumab (Table 3).46 Until pro-
spective registries determine to what extent adalimumab is 
associated with an increased risk of central nervous demy-
elination, use of adalimumab should be avoided in patients 
with a history of MS and patients should be monitored for 
such early signs of demyelinating disease as weakness in the 
limb(s), paresthesias, visual blurring, and ataxia. Through 
Table 2 Safety and tolerability of long-term adalimumab in randomized controlled trials
Study Study design Treatment arms Adverse events (%) Serious adverse events (%, n)
Gordon et al34 12-week double-blind  
placebo-controlled  
randomized trial in Ps;  
open-label extension  
until week 60
Adalimumab  
40 mg weekly  
(n = 50)  
vs 40 mg eow  
(n = 46)  
vs placebo  
(n = 52)
25.2% 
Injection-site pain 3.4%  
Increased blood  
triglycerides 2.3%  
Nausea 1.5%  
Dyspepsia 1.5%
1.9%  
Malignant melanoma (n = 2)  
Breast cancer (n = 1)  
Gastric adenocarcinoma (n = 1) 
Coccidioidomycosis (n = 1)  
Recent onset latent Tb (n = 1)
Menter et al35 16-week double-blind  
placebo-controlled  
randomized trial in Ps;  
re-randomization of  
responders at week 33;  
open label extension  
until week 52
Adalimumab  
40 mg eow  
(n = 814)  
vs placebo  
(n = 398)
55.4%  
Injection-site reaction 3.3% 
Upper respiratory  
tract infection 1.9%  
Nasopharyngitis 1.4%  
Headache 1.3%
0.7%  
Basal cell carcinoma (n = 3)  
Squamous cell carcinoma (n = 3) 
Breast cancer (n = 1)  
Melanoma in situ (n = 1)  
Tuberculosis (n = 1)  
Congestive heart failure (n = 1)
Mease et al41  
Gladman et al42 
Mease et al39 
 
 
 
 
24-week double-blind  
placebo-controlled  
randomized trial in  
Ps and PsA; open label  
extension study to 2 years 
 
 
A dalimumab  
40 mg eow  
(n = 151)  
vs placebo  
(n = 162) 
 
 
Not reported  
Nasopharyngitis 1.8%  
Injection-site reaction 1.2% 
Hypertension 0.9% 
 
 
 
0.6%  
viral meningitis (n = 1)  
Myocardial infarction (n = 2) 
Pulmonary embolism (n = 1)  
Peritoneal tuberculosis (n = 1) 
B-cell non-Hodgkin’s  
lymphoma (n = 1)  
Non-melanoma skin cancer (n = 3)
Abbreviations: eow, every other week; PS, psoriasis; PsA, psoriatic arthritis; TB, tuberculosis.Clinical, Cosmetic and Investigational Dermatology 2010:3 56
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December 2009, no events of progressive multifocal leukoen-
cephalopathy have been reported among subjects participat-
ing in controlled clinical trials on adalimumab or in medical 
published literature.
Because late recurrences of melanoma in RA patients 
receiving anti-TNF-α treatment have been reported,47 patients 
with a history of melanoma have not been eligible in clinical 
trials on adalimumab in psoriasis patients. In these double-
blinded, placebo-controlled, randomized clinical trials on 
psoriasis patients treated with adalimumab, 10 cases of non-
melanoma skin cancers and 3 cases of malignant melanoma 
were observed (Table 2).
In phase II clinical trials on psoriasis patients treated 
with adalimumab, a few patients in each treatment group 
(placebo, 40 mg every other week, 40 mg weekly) converted 
from negative to positive (5.8%, 2.2%, and 12%, respec-
tively), although a greater number of patients converted from 
positive to negative (8%–10%) during the first 12 weeks 
of the trial.34 The most significant autoantibody induction 
occurs early in treatment (in the first year) and stabilizes 
over time. These data (as well as negative to positive shift) 
suggest that only short-term humoral immune responses 
are induced during TNF-α blockade. Through December, 
2009, no cases of lupus have been reported in the medical 
literature after long-term treatment with adalimumab in 
plaque psoriasis.
Deng et al reported 5 cases of interstitial granulomatous 
dermatitis developing in patients treated with a variety of 
TNF-α antagonists, including one patient developing these 
erythematous annular plaques after treatment with adalim-
umab for 1 year (Table 3) and which resolved upon discon-
tinuation of adalimumab.48
There have also been reports of flaring or changing forms 
of existing psoriasis as well development of palmoplantar 
pustulosis in patients with no previous history of psoriasis.49 
Immuno-histochemical staining of skin biopsy specimens 
showed increased staining for IFN-α in anti-TNF-α-induced 
psoriasis compared with patients with non-drug induced 
psoriasis. Collamer et al reviewed all cases of pustular pso-
riasis occurring during anti-TNF-α therapy and concluded 
that new-onset psoriasis may occur any time after initiation 
of anti-TNF-α therapy and often presents with an uncom-
mon morphology or distribution.50 They speculated that 
disruption in cytokine balance following TNF-α inhibition 
may trigger the upregulation of plasmacytoid dendritic cells 
and the subsequent production of unopposed interferon-α. 
Multiple reports on the induction or exacerbation of pso-
riasis in patients treated with TNF-α antagonists exist,51 
including such cases associated with adalimumab as new 
onset generalized pustular psoriasis and52 pustular psoriasis 
of the scalp.51 Although it has been reported to cause pustular 
psoriasis, adalimumab has also been found to be effective in 
the treatment of recalcitrant generalized pustular psoriasis in 
adults53 and adolescents.54 Therefore, adalimumab-induced 
psoriasis requires discontinuation of adalimumab only in 
cases unresponsive to topical anti-psoriatic treatment.
Conclusion
Adalimumab has demonstrated excellent efficacy in moderate 
to severe plaque psoriasis. Based on the current literature on 
the use of adalimumab for plaque psoriasis, no significant 
increase in risk of serious infections is observed, in contrast 
to what has been previously reported in the treatment of RA. 
Due to differences in co-morbidities, adalimumab treatment 
Table 3 Case reports of serious adverse events in psoriasis patients treated with long-term adalimumab
References 
 
Clinical history  
(sex, age, concomitant  
medications)
Duration of  
adalimumab  
prior to SAE
SAE 
 
Resolution of symptoms 
 
Chung et al46 1.   Male, age 55, MTX,  
simvastatin, atenolol,  
aspirin, metformin,  
paroxetine, risperidone
1. Two months 1.   Rapid painless decrease of  
central vision in one eye;  
MRI: retrobulbar optic neuritis
1.   Complete resolution after  
discontinuation of adalimumab
2. Male, age 40, none 2. One year 2.   Progressive visual loss associated  
with painful eye movements.  
MRI: optic neuritis and numerous  
CNS plaques of different ages
2.   Patient continued adalimumab.  
Gradual improvement after  
steroid treatment
Deng et al48 
 
 
Male, age 54, MTX 
 
 
One year 
 
 
Annular erythematous papules on  
thighs and back, clinically and  
histologically consistent with  
interstitial granulomatous dermatitis
Complete resolution after  
discontinuation of adalimumab 
 
Abbreviations: MTX, methotrexate; SAe, serious adverse event; MRI, magnetic resonance imaging; CNS, central nervous system.Clinical, Cosmetic and Investigational Dermatology 2010:3 57
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for patients with moderate to severe plaque psoriasis may 
have less adverse effects compared to RA patients. Prior to 
initiation of adalimumab therapy, however, patients should 
be evaluated for active/latent tuberculosis, serious infections, 
and other contraindications.
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